Departments and Services | For Patients | Research & Trials | Education | Find a Doctor

Division of Infectious Disease
Division of Infections Disease
Fellowship Program
Clinical Programs
Penn CDC Prevention Epicenters Program
Clinical Trials
Botswana-UPenn Partnership
Adjunct Faculty
Administrative Contacts
Outpatient Clinics


faculty photo

Pablo Tebas, M.D.

Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Director, Developmental Core Center for AIDS research (CFAR), Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion. Infectious Disease office.
Clinical Office: Hospital of the University of Pennsylvania. 3400 Spruce Street. Silverstein Pavilion 3rd floor. Suite D.
Philadelphia, Pa 19104
Office: 215-349-8091
Fax: 215-349-8011
Universidad Autónoma de Madrid, Spain, 1985.
Post-Graduate Training
Intern in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1986-1987.
Resident in Medicine, Hospital Puerta de Hierro, Madrid, Spain, 1987-1991.
Fellowship, Infectious Diseases, Washington University in Saint Louis, Missouri, 1992-1995.
Spanish Board of Internal Medicine, 1992.
American Board of Internal Medicine, Internal Medicine, 2004.
American Board of Internal Medicine, Infectious Diseases, 2005.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Jacobson, J. M., Wang, H., Bordi, R., Zheng, L., Gross, B. H., Landay, A. L., Spritzler, J., Routy, J. P., Benson, C., Aberg, J., Tebas, P., Haas, D. W., Tiu, J., Coughlin, K., Purdue, L., Sekaly, R. P., Aids Clinical Trials Group A Protocol Team: A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy. J Acquir Immune Defic Syndr 66(4): 399-406, August 2014.

Sims, K. D., Lemm, J., Eley, T., Liu, M., Berglind, A., Sherman, D., Lawitz, E., Vutikullird, A. B., Tebas, P., Gao, M., Pasquinelli, C., Grasela, D. M.: Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection. Antimicrob Agents Chemother 58(6): 3496-3503, June 2014.

Arribas, J. R., Pialoux, G., Gathe, J., Di Perri, G., Reynes, J., Tebas, P., Nguyen, T., Ebrahimi, R., White, K., Piontkowsky, D.: Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7): 581-9, June 2014.

Barrett, J. S., Bajaj, G., McGuire, J., Wu, D., Spitsin, S., Moorthy, G., Zhao, X., Tebas, P., Evans, D. L., Douglas, S. D.: Modeling and Simulation Approach to Support Dosing and Study Design Requirements for Treating HIV-Related Neuropsychiatric Disease with the NK1-R Antagonist Aprepitant. Curr HIV Res May 2014.

Tebas, P., Sension, M., Arribas, J., Duiculescu, D., Florence, E., Hung, C. C., Wilkin, T., Vanveggel, S., Stevens, M., Deckx, H., on behalf of the, Echo, Thrive Study Groups: Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials. Clin Infect Dis April 2014.

Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., Holmes, M. C., Gregory, P. D., Ando, D. G., Kalos, M., Collman, R. G., Binder-Scholl, G., Plesa, G., Hwang, W. T., Levine, B. L., June, C. H.: Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370(10): 901-10, March 2014.

Ramirez, L. A., Daniel, A., Frank, I., Tebas, P., Boyer, J.: Seroprotection of HIV-Infected Subjects after H1N1-vaccination is Directly Associated with Baseline frequency of Naive T-Cells. J Infect Dis March 2014.

Palella, F. J., Jr., Fisher, M., Tebas, P., Gazzard, B., Ruane, P., Van Lunzen, J., Shamblaw, D., Flamm, J., Ebrahimi, R., Porter, D., White, K., Hindman, J., Elbert, E., De-Oertel, S., Fralich, T.: Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 28(3): 335-44, January 2014.

Grant, P. M., Kitch, D., McComsey, G. A., Dube, M. P., Haubrich, R., Huang, J., Riddler, S., Tebas, P., Zolopa, A. R., Collier, A. C., Brown, T. T.: Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 57(10): 1483-8, November 2013.

Amorosa, V. K., Luetkemeyer, A., Kang, M., Johnson, V. A., Umbleja, T., Haas, D. W., Yesmin, S., Bardin, M. C., Chung, R. T., Alston-Smith, B., Tebas, P., Peters, M. G.: Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naive to HCV therapy: results of the ACTG A5269 trial. HIV Clin Trials 14(6): 274-83, November 2013.

back to top
Last updated: 03/23/2015
The Trustees of the University of Pennsylvania